154 related articles for article (PubMed ID: 37061342)
1. Controlling cell proliferation by targeting cyclin-dependent kinase 6 using drug repurposing approach.
Madhana Priya N; Balasundaram A; Sidharth Kumar N; Udhaya Kumar S; Thirumal Kumar D; Magesh R; Zayed H; George Priya Doss C
Adv Protein Chem Struct Biol; 2023; 135():97-124. PubMed ID: 37061342
[TBL] [Abstract][Full Text] [Related]
2. Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
Yousif FA; Alzain AA; Alraih AM; Ibraheem W
PLoS One; 2023; 18(9):e0291256. PubMed ID: 37682937
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new small-molecule cyclin-dependent kinase 6 inhibitors through computational approaches.
Luo X; Zhao Y; Tang P; Du X; Li F; Wang Q; Li R; He J
Mol Divers; 2021 Feb; 25(1):367-382. PubMed ID: 32770459
[TBL] [Abstract][Full Text] [Related]
4. Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6.
Yousuf M; Shamsi A; Khan P; Shahbaaz M; AlAjmi MF; Hussain A; Hassan GM; Islam A; Rizwanul Haque QM; Hassan MI
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429317
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex.
Khuntawee W; Rungrotmongkol T; Hannongbua S
J Chem Inf Model; 2012 Jan; 52(1):76-83. PubMed ID: 22172011
[TBL] [Abstract][Full Text] [Related]
6. A Search for Cyclin-Dependent Kinase 4/6 Inhibitors by Pharmacophore-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations.
Susanti NMP; Damayanti S; Kartasasmita RE; Tjahjono DH
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948218
[TBL] [Abstract][Full Text] [Related]
7. Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6.
Basati G; Saffari-Chaleshtori J; Abbaszadeh S; Asadi-Samani M; Ashrafi-Dehkordi K
Curr Drug Res Rev; 2019; 11(2):135-141. PubMed ID: 31875784
[TBL] [Abstract][Full Text] [Related]
8. Exploring therapeutic potential of Rutin by investigating its cyclin-dependent kinase 6 inhibitory activity and binding affinity.
Yousuf M; Khan S; Hussain A; Alajmi MF; Shamsi A; Haque QMR; Islam A; Hassan MI
Int J Biol Macromol; 2024 Apr; 264(Pt 2):130624. PubMed ID: 38453105
[TBL] [Abstract][Full Text] [Related]
9. Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation.
Zhou Y; Li X; Luo P; Chen H; Zhou Y; Zheng X; Yin Y; Wei H; Liu H; Xia W; Shi M; Li X
Front Pharmacol; 2023; 14():1154654. PubMed ID: 37234717
[TBL] [Abstract][Full Text] [Related]
10. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
Shukla R; Singh TR
J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
[TBL] [Abstract][Full Text] [Related]
11. Predictive hybrid paradigm for cytotoxic activity of 1,3,4-thiadiazole derivatives as CDK6 inhibitors against human (MCF-7) breast cancer cell line and its structural modifications: rational for novel cancer therapeutics.
Chukwuemeka PO; Umar HI; Iwaloye O; Oretade OM; Olowosoke CB; Oretade OJ; Elabiyi MO
J Biomol Struct Dyn; 2022 Nov; 40(18):8518-8537. PubMed ID: 33890551
[TBL] [Abstract][Full Text] [Related]
12. Designing and optimization of novel human LMTK3 inhibitors against breast cancer - a computational approach.
Anbarasu K; Jayanthi S
J Recept Signal Transduct Res; 2017 Feb; 37(1):51-59. PubMed ID: 27056562
[TBL] [Abstract][Full Text] [Related]
13. Deep-learning based repurposing of FDA-approved drugs against
Joshi T; Pundir H; Chandra S
J Biomol Struct Dyn; 2022 Nov; 40(18):8420-8436. PubMed ID: 33879017
[No Abstract] [Full Text] [Related]
14. In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment.
Zarezade V; Abolghasemi M; Rahim F; Veisi A; Behbahani M
J Mol Model; 2018 Nov; 24(12):337. PubMed ID: 30415281
[TBL] [Abstract][Full Text] [Related]
15. Computational therapeutic repurposing of tavaborole targeting arginase-1 for venous leg ulcer.
Kumar V N; Tamilanban T
Comput Biol Chem; 2024 Aug; 111():108112. PubMed ID: 38843583
[TBL] [Abstract][Full Text] [Related]
16. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
17. Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing.
Baig MH; Yousuf M; Khan MI; Khan I; Ahmad I; Alshahrani MY; Hassan MI; Dong JJ
Front Oncol; 2022; 12():865454. PubMed ID: 35720007
[TBL] [Abstract][Full Text] [Related]
18. Targeting cyclin-dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies.
Yousuf M; Shamsi A; Queen A; Shahbaaz M; Khan P; Hussain A; Alajmi MF; Rizwanul Haque QM; Imtaiyaz Hassan M
J Cell Biochem; 2021 Aug; 122(8):897-910. PubMed ID: 33829554
[TBL] [Abstract][Full Text] [Related]
19. Target-based virtual screening, computational multiscoring docking and molecular dynamics simulation of small molecules as promising drug candidate affecting kinesin-like protein KIFC1.
Khan MKA; Ahmad S; Rabbani G; Shahab U; Khan MS
Cell Biochem Funct; 2022 Jul; 40(5):451-472. PubMed ID: 35758564
[TBL] [Abstract][Full Text] [Related]
20. Targeting CDK6 in hormone receptor-positive breast cancer: inhibitor discovery for precision oncology through dynamics study.
Khatoon Z; Khalid M; Alqarni MH; Foudah AI; Annadurai S; Wahab S; Abdullah Almoyad MA
J Biomol Struct Dyn; 2023 Dec; ():1-13. PubMed ID: 38127416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
